A high-frequency percussive ventilation-based strategy resulted in similar clinical outcomes when compared with a low-tidal volume ventilation-based strategy in burn patients with respiratory failure. However, the low-tidal volume ventilation strategy failed to achieve ventilation and oxygenation goals in a higher percentage necessitating rescue ventilation.
We evaluated vancomycin levels as recent guidelines for therapeutic monitoring of vancomycin (not available at the time these data were collected) recommend trough levels of 15 to 20 μg/mL; however, this may be more difficult to achieve in patients with accelerated vancomycin clearance, such as burn patients or recipients of continuous venovenous hemofiltration (CVVH) therapy. We retrospectively studied 2110 serum vancomycin levels of 171 patients admitted to the burn intensive care unit for more than 4 years and who received vancomycin by continuous infusion (CI) or intermittent infusion (II), with or without simultaneous CVVH. In-hospital mortality, 14- and 28-day mortality following vancomycin therapy were not different between dosing methods, although increased mortality was observed in the subgroup of patients receiving CI vancomycin empirically for clinical sepsis with negative blood cultures. More vancomycin was delivered to patients daily by CI than II, and therapeutic drug monitoring costs were similar. After controlling for differences in vancomycin dose by case matching with propensity scores, mean vancomycin levels were 20.0 ± 3.8 μg/mL for CI, vs 14.8 ± 4.4 μg/mL for II (P < .001). CI dosing resulted in similar levels with or without CVVH, whereas in II dosing, CVVH appeared to significantly decrease vancomycin levels. Although CI dosing was associated with higher vancomycin levels in general and fewer levels of <10 μg/mL, significant nephrotoxicity or neutropenia was not observed. Fifty-seven patients (33.3%) developed bacteremia, and 106 Gram-positive bacteria were recovered, including 63 Staphylococcus aureus. Recurrent bacteremia while receiving vancomycin was infrequent. The 90th percentile minimum inhibitory concentration (MIC₉₀) for vancomycin of 36 available S. aureus isolates tested by broth microdilution was 1.5 μg/mL. CI produced more frequent therapeutic vancomycin levels and less frequent subtherapeutic levels compared to II. However, therapeutic vancomycin levels were achieved infrequently by either method of dosing. Given equivalent therapeutic drug monitoring costs and the lack of a clear clinical benefit, the role of CI dosing remains to be defined in spite of practical and theoretical advantages, particularly when administered in the setting of CVVH.
Despite advances in resuscitation and surgical management of combat wounds, infection remains a concerning and potentially preventable complication of combat-related injuries. Interventions currently used to prevent these infections have not been either clearly defined or subjected to rigorous clinical trials. Current infection prevention measures and wound management practices are derived from retrospective review of wartime experiences, from civilian trauma data, and from in vitro and animal data. This update to the guidelines published in 2008 incorporates evidence that has become available since 2007. These guidelines focus on care provided within hours to days of injury, chiefly within the combat zone, to those combat-injured patients with open wounds or burns. New in this update are a consolidation of antimicrobial agent recommendations to a backbone of high-dose cefazolin with or without metronidazole for most postinjury indications, and recommendations for redosing of antimicrobial agents, for use of negative pressure wound therapy, and for oxygen supplementation in flight.
Implementation of a computer decision support system for burn resuscitation in the intensive care unit resulted in improved fluid management of severely burned patients. All measures of crystalloid fluid volume were reduced while patients were maintained within urinary output targets a higher percentage of the time. The addition of computer decision support system technology improved patient care.
Large body surface area burns pose significant therapeutic challenges. Clinically, the extent and depth of burn injury may mandate the use of allograft for temporary wound coverage while autografts are serially harvested from the same donor areas. The paucity of donor sites in patients with burns involving large surface areas highlights the need for better skin substitutes that can achieve early and complete coverage and retain normal skin durability with minimal donor requirements. We have isolated autologous stem cells from the adipose layer of surgically debrided burned skin (dsASCs), using a point-of-care stem cell isolation device. These cells, in a collagen—polyethylene glycol fibrin-based bilayer hydrogel, differentiate into an epithelial layer, a vascularized dermal layer, and a hypodermal layer. All-trans-retinoic acid and fenofibrate were used to differentiate dsASCs into epithelial-like cells. Immunocytochemical analysis showed a matrix- and time-dependent change in the expression of stromal, vascular, and epithelial cell markers. These results indicate that stem cells isolated from debrided skin can be used as a single autologous cell source to develop a vascularized skin construct without culture expansion or addition of exogenous growth factors. This technique may provide an alternative approach for cutaneous coverage after extensive burn injuries.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.